Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood

@article{Minden2019TimeOD,
  title={Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood},
  author={Kirsten Minden and Gerd Horneff and Martina Niewerth and Eva M. Seipelt and Martin Aringer and Peer Aries and Ivan Foeldvari and Johannes Peter Haas and Ariane Klein and S Tatsis and Klaus Tenbrock and Angela Zink and Jens Klotsche},
  journal={Arthritis Care \& Research},
  year={2019},
  volume={71}
}
To study juvenile idiopathic arthritis (JIA) long‐term outcomes in relation to the time of initiation of biologic disease‐modifying antirheumatic drug (bDMARD). 
Treatment Satisfaction With and Adherence to Disease‐Modifying Antirheumatic Drugs in Adult Patients With Juvenile Idiopathic Arthritis
TLDR
To examine medication satisfaction and adherence and their relationships to disease variables and health‐related quality of life (HRQoL) in adults with juvenile idiopathic arthritis (JIA), a large number of subjects were diagnosed with JIA. Expand
Recent progress in the treatment of non-systemic juvenile idiopathic arthritis
TLDR
In this review, new developments in understanding non-systemic JIA and its treatment will be covered, including a review of currently available biologic modifiers. Expand
Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature
TLDR
Overall the data suggest that flares are common after stopping JIA medications, particularly biologic medications, and promising withdrawal strategies include discontinuing methotrexate beforeBiologic medications in children receiving combination therapy, dose reduction for children on biologics, and treat-to-target approaches to withdrawal. Expand
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
TLDR
It is hypothesized that a guided treat-to-target (T2T) approach is superior to routine care in polyarticular juvenile idiopathic arthritis (pJIA) in terms of reaching a clinical remission after 12 months of treatment. Expand
Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?
TLDR
Remission can be achieved and sustained in (some) JIA patients, regardless of initial treatment, and future studies should focus on predictors (based on imaging-methods or biomarkers) for sustained drug-free remission and flare. Expand
Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach
TLDR
Females with early JIA onset, lower active joint count and ANA positivity were the ones achieving and sustaining remission more frequently, especially when receiving synthetic DMARD alone and in the absence of HLA B27, comorbidities or previous DMARD toxicity. Expand
Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
TLDR
Although there are no ideal biomarkers in JIA, serological biomarkers with potential clinical utility are identified and proposed strategies of combining biomarkers of response to biologics in Jia, as well as routine implementation of clinically acceptable imaging biomarkers for improved disease assessment performance are proposed. Expand
Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics
TLDR
Sacroiliitis was a negative prognostic factor with an increased need for bDMARDs and diminished rates of CR, and early administration of bDMards and compliance improved long-term outcome of ERA. Expand
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
TLDR
Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate. Expand
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
TLDR
The study confirms the effectiveness of ETA even for re-treatment of patients with JIA, and highlights the association of an early bDMARD treatment with a higher rate of inactive disease indicating a window of opportunity. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 58 REFERENCES
Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database
TLDR
The influence of methotrexate (MTX), tumor necrosis factor (TNF) inhibitors, and a combination of the 2 medications on uveitis occurrence in juvenile idiopathic arthritis (JIA) patients is analyzed. Expand
Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000–2013
TLDR
The clinical presentation and medical treatment of patients with systemic juvenile idiopathic arthritis during the first year of illness and 3‐year outcomes in a subsample of patients who were followed up longitudinally are investigated. Expand
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis
To prospectively validate the preliminary criteria for clinical inactive disease (CID) in patients with select categories of juvenile idiopathic arthritis (JIA).
Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry
TLDR
To examine the effects of tumor necrosis factor inhibitors on the risk for serious infections and other influencing factors in a registry, data are collected on patients treated with these drugs over a 12-month period. Expand
Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three‐Variable Juvenile Arthritis Disease Activity Score
To determine cutoff values for defining the states of inactive disease (ID), low disease activity (LDA; or minimal disease activity), moderate disease activity (MDA), and high disease activity (HDA)Expand
How I treat juvenile idiopathic arthritis: A state of the art review.
TLDR
This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both the authors' experience and existing recommendations. Expand
A commentary on TREAT: The trial of early aggressive drug therapy in juvenile idiopathic arthritis
TLDR
The study's main finding that the earlier in the disease course that treatment is started, the better the chance of disease control, has provided evidence that there is a 'window of opportunity' for treating JIA as there is in adult rheumatoid arthritis (RA). Expand
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE–JIA): a multicentre randomised open-label clinical trial
TLDR
In early polyarticular JIA, targeting to achieve minimally active or inactive disease, infliximab plus methotrexate was superior to synthetic DMARD in combination and strikingly superior to metHotrexate alone. Expand
A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study
TLDR
After 3 months of treatment in a randomized trial, patients with recent-onset JIA achieved significantly more clinical improvement on initial combination therapy with MTX / etanercept than on initial MTX or SSZ monotherapy. Expand
Management of juvenile idiopathic arthritis: hitting the target
TLDR
How diverse forms of standardized, guideline-led care and personalized treatment can be combined into a targeted, patient-centred approach to optimize management strategies for patients with JIA is discussed. Expand
...
1
2
3
4
5
...